drugset / Trial / NCT00623480

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment

NCT00623480

Phase 3 Completed 84 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the effect of secondary prophylaxis as compared to episodic treatment on bleeding frequency (number of bleeds per year) and on joint damage.

Timeline

Start
2008-03
Primary completion
2011-09
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ADVATE Protein / enzyme biologic 25 iu/kg Intravenous
Subject ADVATE Protein / enzyme biologic 30 iu/kg Intravenous
Subject ADVATE Protein / enzyme biologic 35 iu/kg Intravenous

Indications